Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preladenant phase 3 placebo-controlled study in moderate to severe Parkinson's disease
2010-020112-11Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of preladenant in Parkinson's disease (PD) (3 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline to week 12 in mean off time. Started Apr 2011; status: completed.
02
Drugs
preladenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2010-020112-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020112-11.